Business Wire

Nearly Two-Thirds of Global Retailers Say Payment Method Flexibility Drives Revenue Growth, ACI Worldwide Survey Finds

9.10.2025 07:00:00 CEST | Business Wire | Press Release

Share

With payments emerging as a battleground for driving revenue growth, global retailers are accelerating their multi-acquirer strategies to stay ahead, according to a new survey conducted by ACI Worldwide (NASDAQ: ACIW) and Payments Dive. The report Unlocking Opportunity: How Payments are Powering Merchant Growth reveals that 97% of global retailers are already working with multiple acquirers, and that 96% of those using two or more acquirers report an increase in revenue. The research also highlights the surge in alternative payment methods (APMs), including real-time payments and cryptocurrencies, as well as the growing importance of AI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007435437/en/

Key Findings at a Glance:

  • Drivers for Multi-Acquiring Strategy: 53% of tier-one global retailers say the need for additional payment options is the top objective when adding additional acquirers, followed by expansion into new markets (51%) and improving authorisation rates (48%). 86% of retailers report cost savings from working with two or more acquirers.
  • Global expansion demands localised payment strategies: 85% of retailers plan to enter new global markets within the next 12 months. To meet local expectations, 69% are adding local acquirers, and 58% are prioritising acquirers that support local payment methods.
  • Rise in cryptocurrency: Crypto is gaining momentum among Millennials and Gen Z. 55% of retailers say cryptocurrency payments influence their choice of acquirer. The growing interest is driven by stablecoins, which offer lower transaction fees and faster settlement.
  • APMs now mainstream: 83% of retailers ranked mobile wallets a top consideration when choosing new acquirers, followed by Account-to-Account payments (67%) and BNPL (57%).
  • Artificial Intelligence (AI) use cases: 70% use AI in acquiring strategies, primarily for fraud detection (65%) and predictive analytics (63%).
  • Payment Orchestration Platforms (POPs): 90% of retailers are using or planning to adopt POPs to streamline multi-acquirer management and enhance fraud prevention.

As retailers scale, managing multiple acquirers becomes increasingly complex. Payment Orchestration Platforms (POPs) provide a powerful solution by unifying acquirers, gateways, and payment methods through a single interface.

"The next wave of retail growth is being driven by AI-powered tools and insights, enabling merchants to optimize performance and increase customer engagement, while embracing emerging payment methods such as mobile wallets, A2A payments, and digital currencies," said Adriana Iordan, global head of merchant, ACI Worldwide. "As retailers adopt a multi-acquiring strategy, the growing complexity underscores the need for smarter payment infrastructure. Intelligent payments orchestration isn't just about improving efficiency; it's about unlocking new revenue streams and transforming payments into a powerful catalyst for revenue uplift."

The full survey report, "Unlocking Opportunity: How Payments are Powering Merchant Growth", is available at www.aciworldwide.com/MA-Survey

-End-

Methodology

This survey, commissioned by ACI Worldwide and conducted by Payments Dive, provides insights from 105 Tier 1 consumer retail leaders, examining how they are using various payment strategies and technologies to manage payments and grow their businesses. All respondents hold senior roles across Payments, Treasury, Finance and IT departments at organizations that operate in the consumer retail industry with a minimum annual revenue of $500 million. The majority of respondents (53%) reported annual revenues between $1 billion and $4.9 billion. The remaining 47% were split between $500 million to $1 billion (23%) and over $5 billion (24%). Respondents indicated that the majority of their business is conducted in either North America (49%) or Europe (51%). The survey was translated into French, German, and Italian to ensure accuracy and cultural relevance across the sample.

About ACI Worldwide

ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and retailers can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.

© Copyright ACI Worldwide, Inc. 2025

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties' trademarks referenced are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007435437/en/

Contacts

Media Contacts
Katrin Boettger | Communications and Corporate Affairs Director I
katrin.boettger@aciworldwide.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye